预约演示
更新于：2025-01-23
Metformin Hydrochloride/Pioglitazone Hydrochloride
吡格列酮二甲双胍
更新于：2025-01-23
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2005-08-29), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H33Cl2N7O3S |
InChIKeyQQPUCHJKWMHONF-UHFFFAOYSA-N |
CAS号737811-27-7 |
关联
57
项与 吡格列酮二甲双胍 相关的临床试验CTR20244521
吡格列酮二甲双胍片在健康受试者中空腹/餐后、单剂量口服、随机、开放、两制剂、两周期生物等效性研究
CTR20244295
吡格列酮二甲双胍片在健康受试者中单剂量口服、随机、开放、两制剂、两周期生物等效性研究
CTR20244046
吡格列酮二甲双胍片人体生物等效性研究
100 项与 吡格列酮二甲双胍 相关的临床结果
登录后查看更多信息
100 项与 吡格列酮二甲双胍 相关的转化医学
登录后查看更多信息
100 项与 吡格列酮二甲双胍 相关的专利（医药）
登录后查看更多信息
9
项与 吡格列酮二甲双胍 相关的文献（医药）2022-03-01Heliyon
Enhanced circulation longevity and pharmacodynamics of metformin from surface-modified nanostructured lipid carriers based on solidified reverse micellar solutions
Article
作者: Isaac, God'spower Tochukwu ; Attama, Anthony Amaechi ; Momoh, Mumuni Audu ; Kenechukwu, Franklin Chimaobi ; Nnamani, Daniel Okwudili
Metformin hydrochloride (MTH) has been associated with poor/incomplete absorption (50-60%), low bioavailability, short half-life (0.4-0.5 h), high dosage and dose-related side effects. To overcome these barriers and improve oral bioavailability and efficacy of MTH, surface-modified nanostructured lipid carriers (NLCs) were developed. Lipid matrices composed of rational blends of beeswax and Phospholipon® 90H (as solid lipids) and Capryol-PGE 860 (as liquid lipid) were prepared by fusion, and the resultant lipid matrices were PEGylated to give 10, 20 and 40% PEGylated lipid matrices. MTH-loaded non-PEGylated and PEGylated NLCs were prepared via high-shear hot homogenization and characterized regarding particle properties and physicochemical performance. The encapsulation efficiencies (EE%) and loading capacities (LC) of the MTH-loaded NLCs were determined while the in vitro drug release was evaluated in phosphate buffered saline (PBS, pH 7.4). Antidiabetic and pharmacokinetics properties of the NLCs were ascertained in an alloxan-induced diabetic rats model after oral administration. The MTH-loaded NLCs were nanomeric (particle size: 184.8-882.50 nm) with low polydispersity index (0.368-0.687) and zeta potential (26.5-34.2 mV), irregular shape, amorphous nature with reduced crystallinity. The EE% and LC were >90 % and 16%, respectively. The formulations showed >65 % release over 12 h in a greater sustained manner than marketed MTH formulation (Glucophage®) as well as enhanced pharmacokinetics properties and sustained blood glucose lowering effect, even at reduced doses with PEGylated NLCs than Glucophage®. Thus, PEGylated NLC is a promising approach for improved delivery and oral bioavailability of MTH thus encouraging further development of the formulation.
2020-04-28Mediators of inflammation3区 · 医学
Pioglitazone Metformin Complex Improves Polycystic Ovary Syndrome Comorbid Psychological Distress via Inhibiting NLRP3 Inflammasome Activation: A Prospective Clinical Study
3区 · 医学
ArticleOA
作者: Hu, Yan-yan ; Huang, Qin ; Zhou, Hui ; Guo, Qing-jun ; Wang, Chao-qun ; Song, Jing-yun ; Shan, Jing ; Huo, Cui-lan ; Xu, Yi-feng ; Yu, Chao-qin
Objective. This study aimed at investigating the therapeutic effect and mechanism of pioglitazone metformin complex preparation (PM) in polycystic ovary syndrome (PCOS) comorbid psychological distress. Methods. Seventy-five patients with PCOS comorbid psychological distress were randomly allocated into the PM, metformin, and placebo groups. The primary efficacy measure was the change from baseline to week 12 on the Symptom Checklist 90-R (SCL-90-R) scores. NLRP3 inflammasome, IL-1β, IL-6, TNF-α, and biochemical parameters were determined at baseline and at week 12. The participants were required to meet the criteria for PCOS (Rotterdam, NIH) and psychological distress (any factor scores of SCL − 90 − R > 2 2.31 ± 0.75 1.65 ± 0.38 p < 0.001 2.08 ± 0.74 1.61 ± 0.46 p = 0.010 98.42 ± 14.38 71.76 ± 13.66 p = 0.02 87.51 ± 8.74 71.98 ± 15.87 p = 0.02 395.33 ± 88.55 281.98 ± 85.69 p = 0.04 2.24 ± 0.74 3.06 ± 0.83 p = 0.024
2017-01-01Journal of clinical medicine research
Effect of Switching From an Anti-Diabetic Loose Dose Combination to a Fixed Dose Combination Regimen at Equivalent Dosage for 6 Months on Glycemic Control in Japanese Patients With Type 2 Diabetes: A Pilot Study
Article
作者: Oka, Masanao ; Kamiyama, Hiroshi ; Aoki, Kazutaka ; Masumura, Makoto ; Nagakura, Mieko ; Taguri, Masataka ; Furuie, Tadashi ; Akema, Noriko ; Terauchi, Yasuo ; Nakajima, Shigeru ; Kamiko, Kazunari
BACKGROUND:
Patients with type 2 diabetes mellitus often take multiple anti-diabetic drugs for a long period. Fixed dose combination (FDC) therapy is expected to improve drug adherence for patients with diabetes. The effect of switching from a loose dose combination (LDC) regimen to an FDC regimen at equivalent dosage on glycemic control has not been evaluated fully. Therefore, we investigated the effect of switching from LDC to FDC at equivalent dosage for 6 months on glycemic control in Japanese patients with type 2 diabetes.
METHODS:
Thirty-eight Japanese patients with type 2 diabetes who were taking anti-diabetic drugs including pioglitazone + metformin, pioglitazone + alogliptin, or pioglitazone + glimepiride were enrolled. These drugs were switched to an FDC of Metact®, Liobel® or Sonias®, respectively, at equivalent dosage. Other anti-diabetic drugs and units of insulin were not changed during the study if possible. HbA1c and body weight were measured 0, 2, 4 and 6 months after switching from an LDC to FDC. We also conducted a questionnaire survey 2 months after the start of the FDC regimen.
RESULTS:
HbA1c levels at 2, 4, and 6 months were not significantly changed compared with prior to switching from an LDC to FDC regimen. Moreover, 74.2% of patients considered decreasing the number of drugs to be "very good" or "good".
CONCLUSION:
HbA1c levels did not differ between patients receiving LDC and FDC therapy at equivalent dosage in this study.
100 项与 吡格列酮二甲双胍 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 感染 | 美国 | 2009-05-12 | |
| 体重下降 | 美国 | 2009-05-12 | |
| 2型糖尿病 | 美国 | 2005-08-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 血脂障碍 | 临床3期 | 德国 | 2007-04-01 | |
| 代谢综合征 | 临床3期 | - | 2007-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 98 | (Pioglitazone and Metformin) | 簾構遞鏇憲鹽選廠繭製(構壓範簾網簾遞範壓淵) = 顧製鑰憲艱繭窪築淵網 鑰廠憲糧鹽鏇鏇範鑰衊 (鹹窪廠築構鏇艱衊糧網, 淵蓋選齋憲廠糧願鏇齋 ~ 艱糧製衊網襯餘壓壓積) 更多 | - | 2014-06-10 | ||
Placebo (Placebo) | 簾構遞鏇憲鹽選廠繭製(構壓範簾網簾遞範壓淵) = 襯廠齋餘淵夢顧選艱蓋 鑰廠憲糧鹽鏇鏇範鑰衊 (鹹窪廠築構鏇艱衊糧網, 簾窪醖糧壓襯醖繭廠鑰 ~ 襯製膚遞糧積壓鏇簾築) 更多 | ||||||
临床3期 | 305 | (Pioglitazone 15 mg and Metformin 850 mg BID) | 觸鏇鑰鹹糧夢齋憲製鑰(醖糧廠窪壓襯鹽選廠遞) = 積積廠鏇餘簾積醖蓋簾 壓繭鑰餘蓋鬱繭齋襯構 (繭觸艱齋選簾艱鏇餘壓, 艱積積夢鹹觸網鑰壓願 ~ 憲築觸齋衊壓齋鹹鏇淵) 更多 | - | 2010-10-06 | ||
(Glimepiride 2 mg and Metformin 850 mg BID) | 觸鏇鑰鹹糧夢齋憲製鑰(醖糧廠窪壓襯鹽選廠遞) = 繭鏇顧積鑰衊積繭壓築 壓繭鑰餘蓋鬱繭齋襯構 (繭觸艱齋選簾艱鏇餘壓, 網簾鹽願築獵鹹鬱網製 ~ 蓋鹽齋繭遞襯築繭夢鹽) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用